STAAR Surgical Company (NASDAQ:STAA) had its target price increased by stock analysts at Benchmark Co. from $12.00 to $13.00 in a research note issued on Monday. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. Benchmark Co.’s target price points to a potential upside of 10.64% from the company’s current price.

STAA has been the subject of a number of other reports. BidaskClub upgraded shares of STAAR Surgical from a “strong sell” rating to a “sell” rating in a report on Friday. Zacks Investment Research downgraded shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Finally, Canaccord Genuity restated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, July 11th.

STAAR Surgical (STAA) traded up 2.340% during midday trading on Monday, hitting $12.025. 61,678 shares of the stock were exchanged. STAAR Surgical has a 52 week low of $7.46 and a 52 week high of $12.05. The stock’s market cap is $494.32 million. The firm’s 50-day moving average is $10.48 and its 200 day moving average is $9.94.

STAAR Surgical (NASDAQ:STAA) last issued its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.04. The firm had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $22.15 million. STAAR Surgical had a negative net margin of 6.06% and a negative return on equity of 8.69%. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.02) earnings per share. Equities research analysts expect that STAAR Surgical will post ($0.12) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/14/staar-surgical-company-nasdaqstaa-price-target-raised-to-13-00-at-benchmark-co.html.

A number of large investors have recently added to or reduced their stakes in the company. Stephens Inc. AR increased its stake in STAAR Surgical by 2.6% in the second quarter. Stephens Inc. AR now owns 12,238 shares of the medical instruments supplier’s stock worth $132,000 after buying an additional 315 shares during the last quarter. Alliancebernstein L.P. increased its stake in STAAR Surgical by 1.7% in the second quarter. Alliancebernstein L.P. now owns 54,300 shares of the medical instruments supplier’s stock worth $586,000 after buying an additional 900 shares during the last quarter. Bank of New York Mellon Corp increased its stake in STAAR Surgical by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 160,186 shares of the medical instruments supplier’s stock worth $1,569,000 after buying an additional 1,392 shares during the last quarter. Strs Ohio increased its stake in STAAR Surgical by 6.2% in the second quarter. Strs Ohio now owns 27,300 shares of the medical instruments supplier’s stock worth $294,000 after buying an additional 1,600 shares during the last quarter. Finally, American International Group Inc. increased its stake in STAAR Surgical by 7.1% in the first quarter. American International Group Inc. now owns 24,648 shares of the medical instruments supplier’s stock worth $242,000 after buying an additional 1,631 shares during the last quarter. Institutional investors own 75.79% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with MarketBeat.com's FREE daily email newsletter.